General Information of Drug (ID: DMY1KE8)

Drug Name
SDZ-224-015 Drug Info
Synonyms VE-13045
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Terminated [1]
Cross-matching ID
PubChem CID
101925102
TTD Drug ID
DMY1KE8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Caspase-1 (CASP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AC-201 DMB0TNL Type-2 diabetes 5A11 Phase 2 [3]
Belnacasan DM2Q50G Epilepsy 8A60-8A68 Phase 2 [4]
PRALNACASAN DM73UTG Rheumatoid arthritis FA20 Phase 2 [5]
Nivocasan DMUX8JZ Fibrosis GA14-GC01 Phase 2 [6]
Ac-YVAD-FMK DM7K256 Allergic contact dermatitis EK00 Patented [7]
Ac-YVAD-cmk DMA1RVN Allergic contact dermatitis EK00 Patented [7]
VE-16084 DMHG70W Rheumatoid arthritis FA20 Terminated [8]
L-709049 DMQZW6D N. A. N. A. Terminated [9]
M826 DM9NPE4 Discovery agent N.A. Investigative [10]
YVAD DM24LNB Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Caspase-1 (CASP1) TTCQIBE CASP1_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006085)
2 Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115(4):601-6.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydr... J Pharmacol Exp Ther. 2007 May;321(2):509-16.
5 Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct;11(10):738-46.
6 Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis. 2013 Dec;18(12):1481-91.
7 Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59.
8 Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine. 1996 May;8(5):377-86.
9 Succinic acid amides as P2-P3 replacements for inhibitors of interleukin-1beta converting enzyme (ICE or caspase 1). Bioorg Med Chem Lett. 2010 Sep 1;20(17):5184-90.
10 Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.
11 Mice deficient in interleukin-1beta converting enzyme resist anorexia induced by central lipopolysaccharide. Am J Physiol. 1999 Nov;277(5 Pt 2):R1435-43.